Cargando…
Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe
INTRODUCTION: Benepali(®) was the first etanercept (Enbrel(®)) biosimilar to be approved in the European Union. Both Benepali and Enbrel are available as autoinjector devices. In a recent survey, nurses from France, Germany, Italy, Spain, and the United Kingdom (UK) reported that their patients with...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127972/ https://www.ncbi.nlm.nih.gov/pubmed/27817152 http://dx.doi.org/10.1007/s40744-016-0048-9 |
_version_ | 1782470315924783104 |
---|---|
author | Thakur, Kunal Biberger, Anna Handrich, Alexandra Rezk, Mourad Farouk |
author_facet | Thakur, Kunal Biberger, Anna Handrich, Alexandra Rezk, Mourad Farouk |
author_sort | Thakur, Kunal |
collection | PubMed |
description | INTRODUCTION: Benepali(®) was the first etanercept (Enbrel(®)) biosimilar to be approved in the European Union. Both Benepali and Enbrel are available as autoinjector devices. In a recent survey, nurses from France, Germany, Italy, Spain, and the United Kingdom (UK) reported that their patients with rheumatoid arthritis (RA) would prefer the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector. To determine whether patients’ perceptions were similar to those of the nurses, this survey evaluated patients’ perceptions and preferences of the Benepali autoinjector versus the Enbrel MYCLIC autoinjector in the same five European countries. METHODS: Patients with RA using the Enbrel MYCLIC autoinjector participated in a 25-min, face-to-face questionnaire-interview. Patients were also shown an instructional video and device-handling leaflet, received a live demonstration on the Benepali autoinjector, and had access to both Benepali and Enbrel MYCLIC training autoinjectors. Patients rated the importance of ten autoinjector attributes on a seven-point scale (1 = not important at all; 7 = extremely important) and provided their autoinjector preferences based on specific attributes. Patients also gave their opinion on which autoinjector they would prefer to use for self-injection. RESULTS: Overall, 220 patients participated in the survey (France, n = 30; Germany, n = 65; Italy, n = 67; Spain, n = 12; UK, n = 46). ‘Easy to operate the self-injection’ was ranked as the most important attribute (mean score of 6.8), followed by ‘easy to grip’ (6.5), and ‘intuitive/self-explaining usage’ (6.3). Patients preferred the Benepali autoinjector, with the attribute of ‘easier to operate’ being a strong differentiator compared to the Enbrel MYCLIC autoinjector. Most patients (74%) reported that they would prefer to use the Benepali autoinjector over the Enbrel MYCLIC autoinjector. ‘Easy to operate the self-injection’ and ‘button-free autoinjector’ were key drivers when selecting an autoinjector. CONCLUSIONS: Patients in Europe reported a preference for the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector. This finding is consistent with results from a recently reported nurse survey. Funding: Biogen. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40744-016-0048-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5127972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-51279722016-12-19 Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe Thakur, Kunal Biberger, Anna Handrich, Alexandra Rezk, Mourad Farouk Rheumatol Ther Original Research INTRODUCTION: Benepali(®) was the first etanercept (Enbrel(®)) biosimilar to be approved in the European Union. Both Benepali and Enbrel are available as autoinjector devices. In a recent survey, nurses from France, Germany, Italy, Spain, and the United Kingdom (UK) reported that their patients with rheumatoid arthritis (RA) would prefer the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector. To determine whether patients’ perceptions were similar to those of the nurses, this survey evaluated patients’ perceptions and preferences of the Benepali autoinjector versus the Enbrel MYCLIC autoinjector in the same five European countries. METHODS: Patients with RA using the Enbrel MYCLIC autoinjector participated in a 25-min, face-to-face questionnaire-interview. Patients were also shown an instructional video and device-handling leaflet, received a live demonstration on the Benepali autoinjector, and had access to both Benepali and Enbrel MYCLIC training autoinjectors. Patients rated the importance of ten autoinjector attributes on a seven-point scale (1 = not important at all; 7 = extremely important) and provided their autoinjector preferences based on specific attributes. Patients also gave their opinion on which autoinjector they would prefer to use for self-injection. RESULTS: Overall, 220 patients participated in the survey (France, n = 30; Germany, n = 65; Italy, n = 67; Spain, n = 12; UK, n = 46). ‘Easy to operate the self-injection’ was ranked as the most important attribute (mean score of 6.8), followed by ‘easy to grip’ (6.5), and ‘intuitive/self-explaining usage’ (6.3). Patients preferred the Benepali autoinjector, with the attribute of ‘easier to operate’ being a strong differentiator compared to the Enbrel MYCLIC autoinjector. Most patients (74%) reported that they would prefer to use the Benepali autoinjector over the Enbrel MYCLIC autoinjector. ‘Easy to operate the self-injection’ and ‘button-free autoinjector’ were key drivers when selecting an autoinjector. CONCLUSIONS: Patients in Europe reported a preference for the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector. This finding is consistent with results from a recently reported nurse survey. Funding: Biogen. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40744-016-0048-9) contains supplementary material, which is available to authorized users. Springer Healthcare 2016-11-05 /pmc/articles/PMC5127972/ /pubmed/27817152 http://dx.doi.org/10.1007/s40744-016-0048-9 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Thakur, Kunal Biberger, Anna Handrich, Alexandra Rezk, Mourad Farouk Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe |
title | Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe |
title_full | Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe |
title_fullStr | Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe |
title_full_unstemmed | Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe |
title_short | Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe |
title_sort | patient perceptions and preferences of two etanercept autoinjectors for rheumatoid arthritis: findings from a patient survey in europe |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127972/ https://www.ncbi.nlm.nih.gov/pubmed/27817152 http://dx.doi.org/10.1007/s40744-016-0048-9 |
work_keys_str_mv | AT thakurkunal patientperceptionsandpreferencesoftwoetanerceptautoinjectorsforrheumatoidarthritisfindingsfromapatientsurveyineurope AT bibergeranna patientperceptionsandpreferencesoftwoetanerceptautoinjectorsforrheumatoidarthritisfindingsfromapatientsurveyineurope AT handrichalexandra patientperceptionsandpreferencesoftwoetanerceptautoinjectorsforrheumatoidarthritisfindingsfromapatientsurveyineurope AT rezkmouradfarouk patientperceptionsandpreferencesoftwoetanerceptautoinjectorsforrheumatoidarthritisfindingsfromapatientsurveyineurope |